A conversation on accelerating innovation in biopharma and life sciences through global collaboration and alliances
DOI:
https://doi.org/10.5912/jcb1004Abstract
We note and reflect on the power of international partnering and collaborations that led to many of the innovations that were brought to market extremely quickly and successfully during the Covid-19 pandemic. These collaborative global approaches suggest the potential for developing broader, open innovation models in more extensive regional and global collaborations for other biopharma and life science market segments. In this article, we adopt a ‘virtual panel discussion format” to frame and discuss potential issues and models that would need to be designed, developed and tested, with the purpose of engaging emerging global regions as equal partners. We also consider similar challenges for regions within countries – even in the US - that lack significant sources for capital across the company life cycle. Several recent open innovation alliance approaches or models are discussed as potential models. They are: the Eli Lilly FIP Net (fully integrated pharmaceutical network); the Enlight Bioscience alliance developed by Pure Tech Ventures; the Harrington Project linking academia to industry; and, the Corporate Accelerator model notably recently expanded globally by Illumina. We outline a proposal to create a guiding coalition, or “think tank” to further test and develop the proposals discussed herein.
Published
Issue
Section
License
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).